Metformin Stada

Metformin Hydrochloride, the active ingredient in Metformin Stada, is a Biguanide presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus. GNH USA supplies Metformin Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Stada belongs to the biguanide class and is indicated for conditions related to impaired glucose regulation.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. Prediabetes: delays progression to overt type 2 diabetes. Polycystic ovary syndrome (PCOS): improves insulin resistance and may aid menstrual regularity.

Metformin Stada may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea or upset stomach - Diarrhea or loose stools - Metallic taste in the mouth - Abdominal discomfort or cramping - Weight loss or reduced appetite - Vitamin B12 deficiency with long‑term use

Serious or Rare Side Effects: - Lactic acidosis, a medical emergency - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatotoxicity or liver enzyme elevation - Hypoglycemia when combined with other antidiabetics - Acute pancreatitis - Anemia or hemolytic events

Before initiating Metformin Stada, several safety considerations should be observed.

Renal function assessment: ensure adequate kidney function before use. Hepatic status evaluation: avoid in patients with significant liver disease. Lactic acidosis risk: discontinue if signs of hypoxia, sepsis, or severe dehydration occur. Elderly monitoring: adjust dose and monitor for accumulation. Concomitant medication review: assess for drugs that may impair renal clearance. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Stada can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: risk of acute renal failure. - Cimetidine: may increase metformin plasma concentrations. - Alcohol excess: heightens lactic acidosis risk. - Diuretics that reduce renal perfusion. - Nifedipine: may affect glucose control.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors or ARBs: monitor renal function. - Other antidiabetic agents: adjust dosing to prevent hypoglycemia. - Warfarin: may alter INR values. - Digoxin: monitor for potential toxicity.